EH3A Amarin Corporation Plc Sponsored ADR

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET.

The conference call with management will follow the release of the Company’s second quarter 2024 financial results in the pre-market hours on July 31st.  

To enhance engagement with the company’s shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow shareholders to submit and upvote questions, a selection of which will be answered by Amarin management during the earnings call. 

Starting on July 17th at 8:00 am ET, all shareholders are encouraged to submit questions by visiting: . This Q&A platform will remain open until 24 hours prior to the start of the earnings call. Shareholders can email  for any support inquiries.

Conference Call and Webcast Information: 

 

Access to the live call: 

Go to the investor relations section of the Company's website at  

Dial in within the United States: 888-506-0062

International dial in: 973-528-0011

Access Code: 409616



Access to replay:
 

Dial in within the United States: 877-481-4010 

International dial in: 919-882-2331  

Access Code: 50766



A replay of the call will also be available through the Company's website shortly after the call. 

About Amarin

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.   

Availability of Other Information About Amarin 

Amarin communicates with its investors and the public using the company website () and the investor relations website (), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. 

Amarin Contact Information   

Investor & Media Inquiries:

Mark Marmur

Amarin Corporation plc







EN
17/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amarin Corporation Plc Sponsored ADR

 PRESS RELEASE

Amarin Reports Third Quarter 2024 Financial Results and Provides Busin...

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update  -- Strong Cash Position of $306 Million; 9th Consecutive Quarter of Positive or Neutral Cash Balance ---- Total Net Revenue of $42 Million Represents Continued Source of Cash from the U.S., RoW Partnerships and Early Phases of European Launches ---- Positive European Momentum Continues with Progress from Pricing & Reimbursement Efforts and Incremental Revenue Growth Driven Primarily by Spain and the UK ---- Company to Host Virtual Analyst & Investor Day November 14 ---- Company Remains Committed to Maintaining...

 PRESS RELEASE

Amarin Announces Two Upcoming Investor Events

Amarin Announces Two Upcoming Investor Events -- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual Analyst & Investor Day Thursday, November 14 -- DUBLIN and BRIDGEWATER, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced two important near-term corporate events: [I] Third Quarter 2024 Financial Results – October 30 – The Company will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, immediately following the close of market trading followed by a conferenc...

 PRESS RELEASE

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosape...

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA®/VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk...

 PRESS RELEASE

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUC...

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presente...

 PRESS RELEASE

Amarin Reports Second Quarter 2024 Financial Results and Provides Busi...

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update -- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch